Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 14/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 14/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mammeisin SCHEMBL31237557 | 1.00 | HIF1A (1.00) | HIF1AEPAS1ABCG2ALDH1A1LMNA | |
| Isomammeisin SCHEMBL6914103 | 0.94 | HIF1A (1.00) | HIF1AEPAS1ABCG2 | |
| Mesuol SCHEMBL29258072 | 0.89 | HIF1A (0.84) | HIF1AEPAS1ABCG2ALDH1A1LMNA | |
| SCHEMBL6914633 | 0.86 | HIF1A (1.00) | HIF1AEPAS1 | |
| Isomesuol SCHEMBL16367909 | 0.84 | HIF1A (0.84) | HIF1AEPAS1ABCG2 | |
| SCHEMBL31237267 | 0.82 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL6907224 | 0.82 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL30927109 | 0.79 | HIF1A (0.71) | HIF1AEPAS1ALDH1A1LMNAHPGD | |
| Isodispar B SCHEMBL29516983 | 0.78 | HIF1A (0.64) | HIF1AEPAS1ALDH1A1LMNAHPGD | |
| SCHEMBL29520661 | 0.74 | HIF1A (1.00) | HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014806-A1 | Methods and compositions for lowering levels of blood lipids | PHARMACIA CORPORATION | 2004-01-22 | — | — | US | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| EP-2735311-A1 | PLANT EXTRACT OBTAINED FROM KIELMEYERA AUREOVINOSA WHICH HAS ANTIBIOTIC ACTIVITY, ISOLATED CHEMICAL COMPOUND, COMPOSITIONS COMPRISING SAME, USES THEREOF AND METHODS FOR PREVENTING AND TREATING BACTERIAL INFECTIONS | Extracta Moléculas Naturais S/A (BR) | 2014-05-28 | — | — | EP | disclosed |
| US-20040014806-A1 | Methods and compositions for lowering levels of blood lipids | PHARMACIA CORPORATION | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014806-A1 | Methods and compositions for lowering levels of blood lipids | SLC10A2, SLC10A1, FABP2 | HIF1A 4785/4885EPAS1 2927/4885ABCG2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.